help button home button Endocrine Society JCEM ENDO 08
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-1810
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/1/98    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow View responses
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, S.
Right arrow Articles by Xing, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, S.
Right arrow Articles by Xing, M.
Related Collections
Right arrow Endocrine Oncology
Right arrow Thyroid
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 1 98-104
Copyright © 2006 by The Endocrine Society

Detection of Serum Deoxyribonucleic Acid Methylation Markers: A Novel Diagnostic Tool for Thyroid Cancer

Shuiying Hu, Marge Ewertz, Ralph P. Tufano, Mariana Brait, Andre Lopes Carvalho, Dingxie Liu, Anthony P. Tufaro, Shehzad Basaria, David S. Cooper, David Sidransky, Paul W. Ladenson and Mingzhao Xing

Division of Endocrinology and Metabolism, Departments of Medicine (S.H., M.E., D.L., D.S.C., P.W.L., M.X.), Otolaryngology-Head and Neck Surgery (R.P.T., M.B., A.L.C., D.S.), and Surgery (A.P.T.), the Johns Hopkins University School of Medicine, Baltimore, Maryland 21287; Division of Endocrinology and Metabolism (S.B.), the Johns Hopkins Bayview Medical Center, Baltimore, Maryland 21224; and Division of Endocrinology and Metabolism (D.S.C.), Sinai Hospital of Baltimore, Baltimore, Maryland 21215

Address all correspondence and requests for reprints to: Mingzhao Xing, M.D., Ph.D., Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287. E-mail: mxing1{at}jhmi.edu.

Context: Serum DNA methylation markers may potentially be useful in diagnosing thyroid cancer and monitoring its recurrence.

Objective: The objective of the study was to assess the utility of serum DNA methylation as a diagnostic test for patients with thyroid nodules and a monitoring test to detect thyroid cancer recurrence in previously treated patients.

Design, Setting, and Subjects: Using real-time quantitative methylation-specific PCR, we analyzed the methylation status of five genes (CALCA, CDH1, TIMP3, DAPK, and RARß2) on 96 bisulfite-treated serum DNA samples isolated preoperatively from either solid thyroid nodule patients or patients in follow-up for history of treated thyroid cancer.

Main Outcome Measure: Diagnostic sensitivity, specificity, and accuracy of serum DNA methylation marker for thyroid cancer were measured.

Results: For the patients with thyroid nodules, when a positive result was defined by a serum methylation level above the appropriately chosen cutoff value for any one of the five genes, the preoperative diagnostic sensitivity for thyroid cancer was 68% (26 of 38), the specificity was 95% (18 of 19), and the overall preoperative diagnostic accuracy was 77%, with positive and negative predictive values of 96 and 60%, respectively. In a subset of patients with cytologically indeterminate thyroid nodules, serum DNA methylation testing could correctly diagnose eight of 11 (73%) cancers and four of four (100%) benign tumors, with a diagnostic accuracy of 80%. We also analyzed these serum DNA methylation markers in 39 previously treated thyroid cancer patients. Among the 10 patients proved to have recurrent disease by conventional measures, seven (70%) were positive on methylation testing. Among the 29 patients who had no corroboration of residual or recurrent disease by conventional studies, six (21%) were positive for serum DNA methylation markers.

Conclusions: We have demonstrated the potential usefulness of serum DNA methylation markers as a novel tool for differential diagnosis of solid thyroid nodules and thyroid cancer recurrence monitoring.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
A. L. Carvalho, C. Jeronimo, M. M. Kim, R. Henrique, Z. Zhang, M. O. Hoque, S. Chang, M. Brait, C. S. Nayak, W.-W. Jiang, et al.
Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., January 1, 2008; 14(1): 97 - 107.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
M Niedziela
Pathogenesis, diagnosis and management of thyroid nodules in children.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 427 - 453.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Is it correct not to apply strategies of modern relative quantification?
Antonio Martinez-Peinado, et al.
JCEM Online, 24 May 2006 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society